A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Phase 1 Terminated 6 enrolled Vincerx Pharma, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 as monotherapy or in combination with a BTKi in patients with Chronic Lymphocytic Leukemia (CLL) or Richter Syndrome

Timeline

Start: 2021-12-16
Primary completion: 2023-05-26
Completion: 2023-05-26

Outcome

Outcome not reported

Stopped (Enrollment): “Slow enrollment”

Publications

Frigault MM, Mithal A, Wong H, Stelte-Ludwig B, Mandava V, Huang X, Birkett J, Johnson AJ, Izumi R, Hamdy A. Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription. Cancer Res Commun. 2023 Nov 9;3(11):2268-2279. doi: 10.1158/2767-9764.CRC-23-0219.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ENITOCICLIB	Small molecule	30 mg	Intravenous